Abstracts tagged "spondyloarthritis"

Abstract Number: 2137 • ACR Convergence 2023
Line of Therapy of Biologics and JAK Inhibitors in RA, PsA and AxSpA: Implications for Design and Uptake of New Drugs and Diagnostics
Jeffrey Curtis¹, Fenglong Xie¹, Yuji Su², Patrick Stewart³ and Amy S. Mudano¹, ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham and Illumination Health, Birmingham, AL, ³Illumination Health, Birmingham, AL
Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA) have an increasing array of treatment options available, and new blood-based diagnostic…
Abstract Number: 2211 • ACR Convergence 2023
A Two-year Comparison of Back Pain and Morning Stiffness in Axial Spondyloarthritis and Non-axial Spondyloarthritis Chronic Back Pain Patients in the Spondyloarthritis Caught Early (SPACE) Cohort
Ana Bento da Silva¹, Miranda Van Lunteren², Mary Lucy marques³, Karen Fagerli⁴, Sofia Ramiro⁵, Désirée van der Heijde⁵ and Floris Van Gaalen², ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ³Leiden University Medical Center; Centro Hospitalar e Universitário de Coimbra (Department of Rheumatology), Coimbra, Portugal, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Treatment of axial spondyloarthritis (axSpA) has been shown to improve symptoms of the disease such as back pain (BP) and morning stiffness (MS). As…
Abstract Number: 2252 • ACR Convergence 2023
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-α Inhibitors Who Were Responders at Week 16: Results from a Phase 3, Randomized Study
William R Tillett¹, Joseph Merola², Yoshiya Tanaka³, Ennio G Favalli⁴, Dennis McGonagle⁵, Diamant Thaçi⁶, Jessica A Walsh⁷, Barbara Ink⁸, Rajan Bajracharya⁸, Jason Coarse⁹ and Christopher T Ritchlin¹⁰, ¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴ASST Gaetano Pini-CTO, University of Milan, Department of Rheumatology, Milan, Italy, ⁵Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, ⁶Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁷Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁸UCB Pharma, Slough, United Kingdom, ⁹UCB Pharma, Morrisville, NC, ¹⁰University of Rochester Medical School, Rochester, NY
Background/Purpose: PsA is a chronic disease affecting multiple domains; however, patients (pts) can experience loss of response with long-term therapy.1 Therefore, maintaining long-term treatment responses…
Abstract Number: 0492 • ACR Convergence 2023
Axial Spondyloarthritis in Patients with Late-Onset Chronic Low Back Pain (Older Than 45 Years). Axial Spa or Psoriatic Disease with Axial Involvement?
rodrigo garcía salinas¹, Gisel Reyes², Rosario Jaldín Céspedes², Felica Almada² and Sebastián Juan Magri³, ¹Arthritis and Spondyloarthritis Unit, Hospital Italiano de La Plata, National University of La Plata, La Plata, Argentina, ²Hospital Italiano de La Plata, La Plata, Argentina, ³Hospital Italiano La Plata, Melchor Romero, Argentina
Background/Purpose: It is known that patients diagnosed with axSpA do not subsequently meet the classification criteria. The Objectives are: To estimate the diagnostic prevalence of…
Abstract Number: 0529 • ACR Convergence 2023
Sex-dependent Differences in Disease Characteristics Do Not Influence Effectiveness of Secukinumab Therapy in Patients with Active Axial Spondyloarthritis in a Non-Interventional Trial (AQUILA)
Michaela Koehm¹, Maximilian Klippstein², Sabine Kugler³, Sina Mackay³, Daniel Schulz³, Asmir Vodencarevic⁴, Guillaume Wendt⁴, Daniel Peterlik⁴, Uta Kiltz⁵, Jan Brandt-Juergens⁶ and Frank Behrens⁷, ¹University Hospital Frankfurt, Frankfurt, Germany, ²Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster of Excellence Immune Mediated Diseases CIMD, Frankfurt, Germany, ³Fraunhofer Institute for Intelligent Analysis and Information Systems IAIS, Fraunhofer Cluster of Excellence Immune Mediated Diseases CIMD, Sankt Augustin, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Goethe-University & Fraunhofer ITMP, Frankfurt, Germany
Background/Purpose: Individualized treatment strategies are of high importance in the treatment of patients with axial spondyloarthritis (axSpA). IL-17A inhibition has demonstrated good efficacy on axSpA.…
Abstract Number: 0981 • ACR Convergence 2023
Time Trends in Overall Infection Risk in Patients with Inflammatory Arthritides Treated with Tumor Necrosis Factor Inhibitors
Aron Hjalti Bjornsson¹, Telma Thrastardottir², Bjorn Gudbjornsson³ and Thorvardur Love⁴, ¹Landspitali University Hospital and the University of Iceland, Reykjavík, Iceland, ²University of Iceland, Reykjavik, Iceland, ³Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁴Landspitali University Hospital and the University of Iceland, Reykjavik, Iceland
Background/Purpose: Infections are a known complication of disease-modifying therapy in rheumatic patients but have also been associated with the diseases being treated. Biosimilars have increased…
Abstract Number: 1402 • ACR Convergence 2023
Exceeding Activity Targets but Missing the Mark with Sleep: Mapping 24-Hour Movement Guidelines in Axial Spondyloarthritis
Laura Passalent¹, Tina Ko¹, Yangqing Deng², Sunita Mathur³, Mark Abovsky⁴, Igor Jurisica⁵, Nigil Haroon⁶ and Robert Inman⁷, ¹Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ²Department of Biostatistics, University Health Network, Toronto, ON, Canada, ³School of Rehabilitation Therapy, Queen's University, Kingston, ON, Canada, ⁴Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, ⁶University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada
Background/Purpose: The Canadian 24-Hour Movement Guidelines were recently published in 2022 and integrate evidence-based targets for physical activity, sleep and sedentary behaviours, with recommendations regarding…
Abstract Number: 1783 • ACR Convergence 2023
Integrative Functional Genomics Points to Natural Killer Cells as Key Drivers in the Pathogenesis of Ankylosing Spondylitis
Marcos Chiñas¹, Daniela Fernandez-Salinas¹, Vitor Aguiar¹, Victor Caballero-Nieto², Micah Lefton³, Joerg Ermann⁴ and Maria Gutierrez-Arcelus¹, ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Montpellier, France, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Multiple lines of evidence indicate that ankylosing spondylitis (AS) is a lymphocyte-driven disease. However, which lymphocyte populations are critical in AS pathogenesis is not…
Abstract Number: 2145 • ACR Convergence 2023
Patterns of Use, Effectiveness, Persistence and Cardiovascular Risk in Patients with Rheumatic Diseases Treated with Upadacitinib in a Real-world Setting. UPAREAL Study
Alicia Garcia Dorta¹, Andrea Hernández Martín², Cristina Rodríguez Regalado³, Sonia Isis Peña Montelongo⁴, Cristina Martínez González⁵, Elena Naveda-González², Enrique González-Dávila⁶, Jose Federico Diaz-Gonzalez⁷ and maría Vanesa Hernández Hernández⁵, ¹Rheumatology Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²Rheumatology Unit, Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, ³Rheumatology Unit, Hospital Universitario Ntra Sra de la Candelaria, Santa Cruz de Tenerife, Spain, ⁴Rheumatology Unit, Hospital Virgen de la Peña, Fuerteventura, Spain, ⁵Rheumatology Unit, Hospital Universitario de Canarias, San Cristobal de la Laguna, Spain, ⁶Department of Mathematics, Statistics and Operation Reseach La Laguna University, La Laguna, Spain, ⁷Hospital Universitario de Canarias, La Laguna, Spain
Background/Purpose: Based mainly on results from a randomized clinical trial (RCT) in rheumatoid arthritis (RA) patients (ORAL Surveillance), major regulatory agencies have concluded that JAK…
Abstract Number: 2212 • ACR Convergence 2023
Interpretation of Disease-specific Questionnaires on Disease Activity, Functional Capacity and Quality of Life in Daily Practice in Axial Spondyloarthritis
Styliani Tsiami¹, Kalliopi Klavdianou², Imke Redeker³, Yaren Elif Özdemir⁴, Philipp Sewerin¹, David Kiefer¹, Ioana Andreica⁵, Uta Kiltz⁶ and Xenofon Baraliakos⁴, ¹Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, ²Asklepieion' General Hospital, Department of Rheumatology, Voula, Kaisariani Athens, Greece, ³Ruhr Universität Bochum, Bochum, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: In axial spondyloarthritis (axSpA), assessment of disease activity and physical function in clinical studies relies on patient-reported outcomes (PRO) such as patient's global, BASDAI,…
Abstract Number: 2437 • ACR Convergence 2023
Translocation of Intestinal Bacteria to Axial and Peripheral Joints in a Model of Spondyloarthropathy
Benjamin Cai¹, Rabina Giri², Helen Benham³, Linda Rehaume¹, Geoffery Strutton³, Anne-Sophie Bergot¹ and Ranjeny Thomas⁴, ¹Frazer Institute, The University of Queensland, Woolloongabba, Australia, ²Mater Research Institute-UQ, Woolloongabba, Australia, ³Princess Alexandra Hospital, Woolloongabba, Australia, ⁴Frazer Institute, The University of Queensland, Brisbane, Australia
Background/Purpose: In spondylarthropathy (SpA), such as psoriatic arthritis (PsA) and ankylosing spondylitis (AS), arthritis is often associated with gut inflammation. After systemic β-1,3-glucan (curdlan) injection,…
Abstract Number: 0501 • ACR Convergence 2023
Multicentre Study of Uveitis in Spondyloarthritis: Prevalence, Characteristics, and Prognosis
Nikolaos Kougkas¹, Konstantina Magiouf², Chrysoula Gialouri³, Gerasimos Evangelatos⁴, Maria Pappa², Afroditi Mpitouli⁵, Alexios Iliopoulos⁶, Theodoros Dimitroulas⁷, Anastasios Karamanakos⁸, Aikaterini Dimouli⁸, Maria Tektonidou², Petros Sfikakis⁹ and George Fragoulis¹⁰, ¹4th Internal Department, Ippokratio Hospital, Aristotle University of Thesaaloniki, Thessaloniki, Greece, ²Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ³National and Kapodistrian University of Athens, Zografou, Greece, ⁴Rheumatology Department, 417 Army Share Found Hospital (NIMTS), Athens, Greece, ⁵Fourth Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, ⁶NIMTS Veterans Hospital, Zografou, Greece, ⁷Aristotle University of Thessaloniki - School of Medicine, Thessaloniki, Greece, ⁸“Evangelismos” General Hospital, Rheumatology Department, Athens, Greece, ⁹National Kapodistrian University of Athens Medical School, Athens, Greece, ¹⁰"Laiko" Hospital - First Department of Propaedeutic and Internal Medicine, Athens, Greece
Background/Purpose: Data are still scarce about risk factors predicting the occurrence and course of uveitis in spondyloarthritis (SpA). We aimed to examine associations between demographic,…
Abstract Number: 0533 • ACR Convergence 2023
Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and b/tsDMARDs in Daily Practice?
Francesco Natalucci¹, Pauline KRUG², Angela DE SOUSA LEITE², Tatiana Sokolova³, Patrick Durez⁴, Maria S. Stoenoiu² and Adrien NZEUSSEU TOUKAP⁵, ¹UCLouvain University, Sermoneta, Italy, ²Cliniques Universitaires Saint-Luc, Brussels, Belgium, ³Université Catholique de Louvain, Brussels, Belgium, ⁴UCLouvain, Brussels, Belgium, ⁵Cliniques universitaires Saint-Luc, St.-Lambrechts-Woluwe, Belgium
Background/Purpose: Randomized-controlled trials (RCTs) done in axial spondyloarthritis (axSpA) patients have shown that remission in axSpA (including nonradiographic axSpA) patients treated without b/tsDMARDs (TNFα blockers,…
Abstract Number: 0991 • ACR Convergence 2023
Trends in Arthroplasty Utilization for Inflammatory Arthritis Including Rheumatoid Arthritis and Spondyloarthritis in China: Analysis of a Large National Database
Dongxing Xie¹, Qiao Jiang², Yuqing Wang², Huizhong Long², Hu Chen³, Jie Wei⁴, Xiaoxiao Li⁵, Haibo Wang⁶, Chao Zeng⁷ and Guanghua Lei⁷, ¹Xiangya Hospital, Central South University, Changsha, China, ²Xiangya Hospital, Changsha, China, ³Tibet Autonomous Region People’s Hospital, Lhasa, China, ⁴Health Management Center, Xiangya Hospital Central South University, Changsha, China, ⁵Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, ⁶China Standard Medical Information Research Center, Shenzhen, China, ⁷Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China
Background/Purpose: For end-stage inflammatory arthritis (IA) including rheumatoid arthritis (RA) and spondyloarthritis (SpA), joint arthroplasty is the only treatment option, but is considered to be…
Abstract Number: 1403 • ACR Convergence 2023
MRI-defined Sacroiliitis in First Degree Relatives of Ankylosing Spondylitis Patients
Kristyna Bubova¹, Lenka Hasikova², Katerina Mintalova², Monika Gregova², Sarka Forejtova², Ladislav Senolt³ and Karel Pavelka⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic, ⁴Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic
Background/Purpose: Sacroiliitis is a main radiographic finding in axial spondyloarthritis (axSpA) - the inflammatory rheumatic disease with a strong genetic background. The aim of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].